Onward Medical N Adds Novel Brain-Spine Interface and Parkinson’s Disease Intellectual Property to Licensing Agreements

ONWARD adds new brain-spine interface and Parkinson’s disease

Licensing agreements between intellectual property and disease

ONWARD obtains the rights to breakthrough innovations in brain-spine interface and Parkinson’s disease

EINDHOVEN, The Netherlands & LAUSANNE, Switzerland – March 28, 2022 – ONWARD Medical NV (Euronext: ONWD), the medical technology company that creates innovative therapies to restore movement, independence and health to people with spinal cord injuries. spinal cord (LME), today announces that two new innovations have been added to its portfolio of licensing agreements with the Ecole polytechnique fédérale de Lausanne (EPFL), one of the world’s leading neuroscience research institutions , and the Vaudois University Hospital Center (CHUV), ranked among the 10 best hospitals in the world.

ONWARD has obtained the rights to exploit the intellectual property of EPFL and CHUV to develop and commercialize the following therapies currently being evaluated in clinical feasibility studies conducted by .NeuroRestore,a leading center for neuro-restorative therapies:

  • – Restore mobility (standing, walking, etc.) and upper limb function using a wireless brain-spine interface (BSI) that picks up brain signals recorded by a brain implant to trigger stimulation of the spinal cord, restoring voluntary control of paralyzed arms and legs. This therapy is being studied for its clinical feasibility in the STIMO-BSI trial: brain-controlled spinal cord stimulation in patients with spinal cord injury); and

  • – Attenuate gait disturbances (freezing of gait, etc.) in people with Parkinson’s disease by stimulating the spinal cord, based on the knowledge acquired in the STIMO A trial that showed that programmed, targeted spinal cord stimulation can restore the ability to stand and walk even after complete spinal cord injury. This therapy is being studied for its clinical feasibility in the STIMO-Park trial: feasibility study of targeted epidural spinal stimulation to improve mobility in patients with Parkinson’s disease).

In the United States and Europe, 650,000 people with spinal cord injury could benefit more from brain-spine interface technology when used in combination with ONWARD’s ARC therapy, allowing them potentially standing and walking again. Nearly one million people in the United States and Europe suffer from gait disturbances due to Parkinson’s disease; spinal cord stimulation via ARC Therapy can maintain their ability to walk and maintain their independence and quality of life despite their neurodegenerative condition.

“These new rights are in addition to ONWARD’s impressive portfolio of patents and exclusive licenses with the world’s leading neuroscience research laboratories,” said Dave Marver, CEO of ONWARD. “Our work with EPFL and CHUV on therapies exploiting a brain-spine interface can help a broader group of people with spinal cord injuries recover and optimize upper limb mobility and function. We also look forward to further exploring and potentially commercializing therapies that can restore and preserve mobility in people with Parkinson’s disease, although our current focus remains to serve the SCI community.”

To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health to people with spinal cord injury, please visitONWD.com.


ONWARD is a medical technology company that creates innovative therapies to restore movement, independence and health to people with spinal cord injuries. ONWARD’s work is based on more than a decade of basic and preclinical scientific research conducted in leading neuroscience laboratories around the world. ONWARD’s ARC Therapy, which can be delivered via implantable (ARCI AM) or external (ARCEX), is designed to provide targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injuries, thereby improving their quality of life. ONWARD has received three breakthrough device designations from the FDA encompassing both ARCI AM and CRAEX. The company’s first pivotal FDA trial, called Up-LIFT, was completed in December 2021 with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It has an office in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts, USA. For more information about the company, please visit ONWD.com. To access our 2022 Financial calendar, please visit IR.ONWD.com.

For media inquiries: [email protected] +44 (0)20 3757 6772

For investor inquiries: [email protected]

For business inquiries: FORWARD [email protected]d.com


Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations and projections of the Company or, if applicable, the directors of the Company regarding future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including but not limited to changes in demand, competition and technology, may cause actual events, performance or results to differ materially from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Accordingly, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements contained in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company, its advisors or representatives, nor any of its subsidiaries or the officers or employees of such persons warrant that the assumptions underlying these forward-looking statements

statements are free from error and accepts no responsibility for the future accuracy of any forward-looking statements contained in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.